This forum is for the discussion of anything to do with Prostate Cancer. There are only four rules:
No fundraisers, no commercials (although it is OK to recommend choices of treatment or medical people based on your personal research; invitations to participate in third-party surveys are also acceptable, provided there is no compensation to YANA);
No harvesting e-mail addresses for Spam;
No insults or flaming - be polite and respectful at all times and understand that there may be a variety of points of view, all of which may have some validity;
Opinions are OK, but please provide as much factual evidence as possible for any assertions that you are making
Failure to abide by these simple rules will result in the immediate and permanent suspension of your posting privileges.
Since this is an International Forum, please specify your location in your post.
FDA Approves a Highly Sensitive Prostate Cancer Imaging Agent
I was diagnosed with Prostate Cancer in 2007. Doctor removed prostate with robot, 2013 Radiation. PSA now creeping up again.
May 27, 2021
Breaking News: FDA Approves a Highly Sensitive Prostate Cancer Imaging Agent
https://www.pcf.org/blog/breaking-news-fda-approves-a-highly-sensitive-prostate-cancer-imaging-agent/
Just stumbled on this link. Still not certain what it's all about but sounds promising.
Partial quote from site listed above:
PyL PET imaging is approved for two types of patients with prostate cancer: 1) those with suspected metastasis who are candidates for initial definitive therapy (e.g., newly diagnosed with high-risk disease) and 2) those with suspected recurrence based on elevated PSA level (e.g. who previously had their prostate cancer treated, and are now seeing their PSA rise, in order to determine if and where they have metastases).
Re: FDA Approves a Highly Sensitive Prostate Cancer Imaging Agent
PYL is approved but will not show up in many institutions for months. The scan most common is Axumin but has technically been displaced by a scan called PSMA PET that was only approved at UCLA and USCF in California.
Neither of these are yet approved by the all knowing Medicare. Cash only $3300. MD Anderson in Houston has a trial that is open for patients with >.2 ng/dl where they are testing PSMA PET capabilities. Not sure of any other constraints.
PSMA PET scans coming to a facility near you and will likely change the landscape of how you monitor your cancer status.
